• Record sales of A$4.0 million for HY25, up 70% on prior year
• Immuron plans Phase 2 trial for IMM-529 to treat Clostridioides difficile infection
• Positive FDA feedback on pre-IND for IMM-529, forecasts peak sales of US$400 million

Immuron Limited has reported a loss for the half-year ended 31 December 2024 of A$2,488,819, up 20% on the prior year. The group's net assets decreased to A$10,339,516 compared with A$12,709,484 at 30 June 2024, including cash reserves of A$7,736,399. Revenue from ordinary activities for the half-year was A$3,994,341, up 69.6% on the prior year, driven by strong sales of the company's Hyperimmune products. Gross profit was A$2,657,049. Key highlights for the period include record sales of A$4.0 million for HY25, up 70% on the prior year; plans to file an IND and initiate a Phase 2 trial for IMM-529 to treat Clostridioides difficile infection following positive FDA feedback on the pre-IND filing; an updated peak sales forecast for IMM-529 in C. difficile infection increased from US$93 million to US$400 million; completion of 100% recruitment for the Travelan® Phase 4 clinical trial; and the submission of the Travelan® Phase 2 clinical study report to the FDA. Immuron also announced a new research collaboration with Monash University targeting antimicrobial resistance.

Immuron plans to file an investigational new drug (IND) application for IMM-529 to prevent or treat Clostridioides difficile infection (CDI) during the first half of 2025, followed by a Phase 2 trial of IMM-529 in individuals with CDI.